Wuhan YZY Biopharma Co (HKSE:02496) Total Liabilities: HK$251.92 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Wuhan YZY Biopharma Co Total Liabilities?

Wuhan YZY Biopharma Co HKSE:02496 Total Liabilities is HK$251.92 Mil as of Dec. 2025. The stock has 8 warning signs investors should review.

Wuhan YZY Biopharma Co's Total Liabilities for the quarter that ended in Dec. 2025 was HK$251.92 Mil.

Wuhan YZY Biopharma Co's quarterly Total Liabilities increased from Dec. 2024 (HK$253.37 Mil) to Jun. 2025 (HK$291.93 Mil) but then declined from Jun. 2025 (HK$291.93 Mil) to Dec. 2025 (HK$251.92 Mil).

Wuhan YZY Biopharma Co's annual Total Liabilities increased from Dec. 2023 (HK$190.29 Mil) to Dec. 2024 (HK$253.37 Mil) but then declined from Dec. 2024 (HK$253.37 Mil) to Dec. 2025 (HK$251.92 Mil).

Wuhan YZY Biopharma Co Total Liabilities Historical Data

* Premium members only.

The historical data trend for Wuhan YZY Biopharma Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Wuhan YZY Biopharma Co Total Liabilities Chart

Wuhan YZY Biopharma Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
69.78 164.11 190.29 253.37 251.92

Wuhan YZY Biopharma Co Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Liabilities Get a 7-Day Free Trial 190.29 226.47 253.37 291.93 251.92

Wuhan YZY Biopharma Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Wuhan YZY Biopharma Co's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=221.537+(30.38+-3.5527136788005E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=251.92

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=193.335--58.582
=251.92

Wuhan YZY Biopharma Co's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=221.537+(30.38+-3.5527136788005E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=251.92

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=193.335--58.582
=251.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of HK$251.92 Mil mean?
Wuhan YZY Biopharma Co (HKSE:02496) has a Total Liabilities of HK$251.92 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Wuhan YZY Biopharma Co and its competitors.
Is Wuhan YZY Biopharma Co's Total Liabilities too high?
Wuhan YZY Biopharma Co's current Total Liabilities is HK$251.92 Mil.
How does Wuhan YZY Biopharma Co's Total Liabilities compare to VRTX and REGN?
Wuhan YZY Biopharma Co's Total Liabilities of HK$251.92 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Wuhan YZY Biopharma Co and its competitors. Wuhan YZY Biopharma Co's current Total Liabilities is HK$251.92 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wuhan YZY Biopharma Co stock overvalued right now?
Wuhan YZY Biopharma Co (HKSE:02496) has a current Total Liabilities of HK$251.92 Mil. The current Total Liabilities is HK$251.92 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Wuhan YZY Biopharma Co (HKSE:02496), the current Total Liabilities is HK$251.92 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Wuhan YZY Biopharma Co Business Description

Address No. 666 Gaoxin Road, Building C2-1, Optics Valley Bio-City, East Lake High Tech Development Zone, Hubei Province, Wuhan, CHN
Wuhan YZY Biopharma Co Ltd is a biotechnology company dedicated to developing bispecific antibody (BsAb)- based therapies. The Company has been forward-looking in deploying its presence in several therapeutic fields, including but not limited to tumor-associated complications, tumors, ophthalmology, and autoimmune diseases. The Company also proactively established several self-developed technology platforms, such as Y-BODY, Check-Body, and Nano-Ybody, promoting the development of more candidates to clinical stages with high efficiency.